Adenosine vs Diltiazem for Treatment of SVT in the ED

Recruitment Status
RECRUITING
(See Contacts and Locations)Verified April 2026 by Anne E. Zepeski
Sponsor
Anne E. Zepeski
Information Provided by (Responsible Party)
Anne E. Zepeski
Clinicaltrials.gov Identifier
NCT06993038
Other Study ID Numbers:
202412202
First Submitted
April 2, 2025
First Posted
May 27, 2025
Last Update Posted
May 27, 2026
Last Verified
April 2026

ClinicalTrials.gov processed this data on May 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Condition or DiseaseIntervention/Treatment
Supraventricular Tachycardia (SVT)
Drug: adenosineDrug: diltiazem

Study Design

Study TypeInterventional
Actual Enrollment20 participants
Design AllocationRandomized
Interventional ModelSingle Group Assignment
MaskingSingle
Primary PurposeTreatment
Official TitleCOMparison of Adenosine Versus Diltiazem FOR Supraventricular Tachycardia in the ED (COMFORT-ED) - Pilot Trial
Study Start DateJuly 31, 2025
Actual Primary Completion Date10mos 2w from now
Actual Study Completion Date1yr 3mos from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Adenosine
Drug: adenosine
IV adenosine at standard doses for SVT (6 mg, 12 mg)
Diltiazem
Drug: diltiazem
IV diltiazem at standard doses for SVT (0.25 mg/kg)

Outcome Measures

Primary Outcome Measures
  1. Feasibility outcome
    Patients with stable SVT are identified in the ED (Threshold \>90%)
  2. Feasibility outcome
    Eligible participants who provide consent to participate (Threshold \>50%)
  3. Feasibility outcome
    Participants who complete all study procedures (Threshold \>80%)

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
1. Adult patients (18 years and older) 2. Diagnosis of acute, stable SVT in the emergency department
Exclusion Criteria
1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting). 2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome 3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%) 4. Severe bronchoconstrictive lung disease 5. Prior hypersensitivity to study medication 6. Previously enrolled in pilot study 7. Pregnant 8. Incarcerated

Contacts and Locations

Sponsors and CollaboratorsAnne E. Zepeski
Locations
University of Iowa Health Care | Iowa City Iowa, United States, 52242
Investigators
Principal Investigator: Anne Zepeski, PharmD, University of Iowa